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I n their recently published researchstudy, Gargano et al. found that a
physician’s recommendation and paren-
tal health beliefs had significant effects
on adolescent vaccination rates and on
parental intentions to vaccinate. This
research replicates the findings of a num-
ber of human papillomavirus (HPV) vac-
cine-focused research studies, but
explores new territory by focusing on all
recommended adolescent vaccines:
meningococcal-conjugate (MCV4),
HPV, influenza, and tetanus, diphtheria,
and acellular pertussis (Tdap) vaccines.
Although Gargano et al.’s study is rela-
tively small in scale and focuses on only
one county in Georgia, their results are
consistent with many other research
reports, suggesting that their findings are
robust and replicable. Most published
intervention studies have targeted
parents and young adults, with little
focus on health care professionals. How-
ever, given the centrality of physician rec-
ommendation in adolescent vaccination,
as shown by Gargano et al., it is clear
that the time has come to develop and
evaluate interventions that help physi-
cians and other health care professionals
to more effectively implement strong and
routine recommendations for all adoles-
cent platform vaccines.
Gargano et al. report the results of an
interesting study on parental attitudes
about adolescent vaccination.1 One of
their primary findings is that physician
recommendation of vaccination is a pri-
mary reason for parents to vaccinate or
intend to vaccinate their adolescent sons
and daughters. Doctor recommendation
was a significant predictor of adolescent
receipt of meningococcal-conjugate
(MCV4), human papillomavirus (HPV),
and tetanus, diphtheria, and acellular per-
tussis (Tdap) vaccines. For adolescents
who had not yet received a given vaccine,
doctor recommendation was significantly
associated with parental intention to vacci-
nate with MCV4, HPV, and Tdap.
The question arises, however, what can
be made of the results of this relatively
small-scale study (n D 114) from a single
county in the state of Georgia in the
United States, particularly given that the
central importance of health care profes-
sional (HCP) recommendation/non-rec-
ommendation has been documented in
several previous research studies on HPV
vaccination?2-7 In fact, a recently pub-
lished review paper on adolescent HPV
immunization identified 17 research
articles related to HCP recommendation
of HPV vaccination.8 Moreover, research
on physicians tends to corroborate paren-
tal reports, indicating inconsistent
practices around HPV vaccine recommen-
dations and a tendency among some pro-
viders to delay initiation of vaccination
until after the targeted age of
11–12 years,9-11 an issue also summarized
in the aforementioned review article.8
Where Gargano et al. make a signifi-
cant contribution and move the field for-
ward is in their inclusion of vaccines other
than HPV. In a chapter published in 2013
that I co-authored we pointed out that the
number of behavioral science research
studies on HPV vaccination far out-
stripped research on other adolescent vac-
cines.12 This disparity has only risen over
the past year. Although the fascination of
behavioral and social science researchers
with HPV vaccination is somewhat under-
standable, there are consequences to this
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fairly exclusionary focus on one vaccine.
For one, it reinforces the notion that HPV
vaccine is different from other vaccines,
which may lead it to be treated differently
by parents and HCPs compared with the
other routinely recommended adolescent
platform vaccines. Furthermore, it sug-
gests that we have relatively little to learn
about influenza, MCV4, and Tdap vacci-
nation of adolescents, which is certainly
untrue, as evidenced by the research
reported by Gargano et al. A recent Aus-
tralian article published by Marshall et al.
focused on parental attitudes about a new
meningococcal serogroup B vaccine.13 In
this study, as in Gargano et al.’s, physician
recommendation was one of the strongest
predictors of parental intent to vaccinate.
The fact that a study from a county within
the state of Georgia reports findings com-
parable to those from the state of South
Australia suggests that Gargano’s et al.’s
results are robust and meaningful, despite
the relatively small sample size and narrow
geographical range.
A second set of findings from Gargano
et al. is that parental health beliefs are
associated with vaccine receipt and inten-
tion. As with physician recommendation,
these kinds of associations are well-
documented in the vaccine literature, and
research on parental health beliefs and
immunization goes back to the early days
of polio vaccination.14 Nonetheless, it is
helpful to see confirmation of these find-
ings across several adolescent vaccines and
it is a useful reminder that parental beliefs,
which may be modifiable, can act as an
obstacle to, or facilitator of, adolescent
vaccination.
Given the centrality of health care pro-
vider recommendation to adolescent vac-
cination, as identified by Gargano et al.
and others, we are led to consider what
can be done to help ensure that physicians
and other HCPs routinely and strongly
recommend all adolescent vaccines, partic-
ularly during the targeted ages of 11–12.
Clearly, what is needed is a concerted
effort to develop and evaluate interven-
tions that target HCPs with the goal of
increasing adolescent vaccination rates,
particularly for HPV and influenza vac-
cines, which, nationally, have lagged
behind MCV4 and Tdap.15,16 To date,
most HPV vaccine intervention research
has focused on parents and youth/young
adults.17 I am aware of only one published
study that has tested an intervention with
HCPs.18,19 In this study an electronic
medical record decision support interven-
tion showed some promising results. Bar-
ring significant and wide-spread changes
in adolescent immunization policy, I
would argue that our best opportunity to
increase adolescent vaccination rates will
be to identify and implement effective
ways to help HCPs make strong, routine
recommendations for all adolescent plat-
form vaccines. Gargano et al. confirm the
importance of a physician’s recommenda-
tion in parental acceptance of adolescent
vaccination. The time has come to begin
to act on these findings to ensure that our
youth are maximally protected from the
potentially harmful effects of meningococ-
cal, HPV, influenza, and pertussis
infections.
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